262 related articles for article (PubMed ID: 27401557)
21. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
22. Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program.
Maroun CR; Naujokas MA; Park M
Mol Biol Cell; 2003 Apr; 14(4):1691-708. PubMed ID: 12686619
[TBL] [Abstract][Full Text] [Related]
23. Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5.
Wang Z; Ge L; Wang M; Carr BI
Hepatology; 2007 Dec; 46(6):2003-13. PubMed ID: 18046719
[TBL] [Abstract][Full Text] [Related]
24. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
25. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Pavan S; Musiani D; Torchiaro E; Migliardi G; Gai M; Di Cunto F; Erriquez J; Olivero M; Di Renzo MF
Int J Cancer; 2014 Mar; 134(6):1289-99. PubMed ID: 23996744
[TBL] [Abstract][Full Text] [Related]
26. A role for Grb2-associated binder-1 in growth hormone signaling.
Kim SO; Loesch K; Wang X; Jiang J; Mei L; Cunnick JM; Wu J; Frank SJ
Endocrinology; 2002 Dec; 143(12):4856-67. PubMed ID: 12446613
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway.
Ueoka Y; Kato K; Wake N
Mol Cell Endocrinol; 2003 Apr; 202(1-2):81-8. PubMed ID: 12770735
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
29. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation.
Wong AS; Roskelley CD; Pelech S; Miller D; Leung PC; Auersperg N
Exp Cell Res; 2004 Sep; 299(1):248-56. PubMed ID: 15302591
[TBL] [Abstract][Full Text] [Related]
30. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Herynk MH; Zhang J; Parikh NU; Gallick GE
J Exp Ther Oncol; 2007; 6(3):205-17. PubMed ID: 17552361
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
33. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells.
Zhou HY; Wong AS
Endocrinology; 2006 May; 147(5):2557-66. PubMed ID: 16469801
[TBL] [Abstract][Full Text] [Related]
34. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
[TBL] [Abstract][Full Text] [Related]
35. Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions.
Chan PC; Sudhakar JN; Lai CC; Chen HC
Oncogene; 2010 Feb; 29(5):698-710. PubMed ID: 19881549
[TBL] [Abstract][Full Text] [Related]
36. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
37. The involvement of the docking protein Gab1 in mitogenic signalling induced by EGF and HGF in rat hepatocytes.
Aasrum M; Ødegård J; Sandnes D; Christoffersen T
Biochim Biophys Acta; 2013 Dec; 1833(12):3286-3294. PubMed ID: 24126105
[TBL] [Abstract][Full Text] [Related]
38. FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells.
Zhang Y; Xiong X; Zhu Q; Zhang J; Chen S; Wang Y; Cao J; Chen L; Hou L; Zhao X; Hao P; Chen J; Zhuang M; Li D; Fan G
Elife; 2022 May; 11():. PubMed ID: 35550247
[TBL] [Abstract][Full Text] [Related]
39. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
40. Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression.
Oneyama C; Yoshikawa Y; Ninomiya Y; Iino T; Tsukita S; Okada M
Oncogene; 2016 Jan; 35(4):501-12. PubMed ID: 25867068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
